Author: Ian Conway

Ian Conway has worked in financial markets for over 30 years as a bond and equity trader, Extel-rated analyst and strategist, and partner of a stockbroking firm. He also founded a financial research company servicing institutional clients prior to writing for and editing Shares magazine. Ian is primarily an income investor although he also buys selected growth stocks. Find him at LinkedIn: Click Here

Berkeley Group sees no upturn in housing market

In its AGM trading update, developer Berkeley Group (LON:BKG) said it had seen no upturn in the housing market since April. The firm said the ongoing Middle East conflict and political change had further impacted sentiment and core economic indicators. Profits to be H1 weighted Although enquires are ‘good and stable’, only customers who have finance and need to move are buying properties. Customers who don’t need to move immediately and without readily available liquidity ‘remain more cautious to commit’. Moreover, the firm expects some customers to defer buying until after the Budget at the end of October. As it…

Read More
Frontier Developments beats forecasts and announces special dividend

AIM-listed games developer Frontier Developments (LON:FDEV) posted forecast-beating FY26 results and announced a £5 million special dividend. For the year to May, the firm posted record revenue, earnings and cash generation, enabling it to make the extra payout. Operating profit beats forecasts Revenue for the year to May 2026 rose 16% to £104.8 million, in line with the most recent upgraded guidance. Adjusted operating profit rose 62% to £21.4 million, comfortably above the latest upgraded forecast of £19 million. Sales were driven by the success of Jurassic World Evolution 3 and the continued popularity of the Planet Coaster and Planet…

Read More
James Fisher confirms FY guidance

Marine services group James Fisher (LON:FSJ) maintained its trading momentum in H1 and confirmed its FY26 profit guidance. The firm said strong trading in Defence and Maritime had offset the impact of short-term softness in the Energy division. Positive momentum maintained in H1 Group revenue rose 2.1% to £195.9 million, although performance was mixed across the group. Increased activity in Defence and Maritime Services offset weakness in Energy Services caused by geopolitical uncertainty. Defence revenue jumped 43% with a substantial increase in operating margins thanks to positive mix and operational gearing. Martime Services revenue grew 8%, also with improved operating…

Read More
EasyJet flies in to FTSE 100

Shares in low-cost airline EasyJet (LON:EZJ) will fly back into the FTSE 100 index as part of the latest quarterly index review. Meanwhile, betting firm Entain (LON:ENT) and housebuilder Persimmon (LON:PSN) will exit the index and be relegated to the FTSE 250. All changes will be implemented at the close on Friday 18 September and take effect from the open on Monday 21 September. EasyJet flies in, briefly The reason behind EasyJet rejoining the premier index of UK stocks is the Apollo bid, which caused the share price to spike. Apollo offered 715p per share, seeing off a rival bid…

Read More
Concurrent Technologies jumps on record H1 results and order book

Shares in AIM-listed computer products maker Concurrent Technologies (LON:CNC) jumped after the firm posted record H1 results. Investors also picked up on the exceptional growth in new orders with intake up 110% in H1. Record H1 results For the six months to June, Concurrent posted record revenue of £23.2 million. Product revenue rose 10.6% to £19.8 million, while Systems revenue rose 9% to $4.6 million (£3.4 million). The firm noted its continued progress in turning previous design wins into production programmes. New wins during H1 represent an estimated lifetinme value of aroound £129 million. Order intake increased 110% to £36.9…

Read More

In the latest episode, the chaps talk through the positive tone of recent UK and US corporate updates. Steve also explains why, good as they were, results from Broadcom (NASDAQ:AVGO) failed to ignite the shares. Once again, it seems, the market had already priced in sky-high expectations. On the other hand, the stellar reaction to results from Snowflake (NYSE:SNOW) suggests investors were under-pricing growth. Steve then digs into the Gamma Communications (LON:GAMA) takeover and asks if investors are giving the business away. Ian reflects on the upbeat tone of UK results commentaries this week. Companies from wealth manager Brooks Macdonald (LON:BRK)…

Read More
Coming next week: Adobe, Associated British Foods and Computacenter

The week of 7–11 September 2026 is set to be a busy one for UK retail investors, with a strong mix of technology, consumer, retail and business services results. Monday gets the week moving with ‘in-play’ Gamma Communications, plus IQE, SigmaRoc and Standard Life, while Tuesday’s Computacenter (more detail below) and Dunelm results should attract particular attention given their relevance to UK technology spending and household consumption. Gamma Communications: Why Epiris buyout is a loss for UK market and investors Wednesday brings updates from Associated British Foods, Gym Group and Frontier Developments, before Thursday becomes a key day. Currys, Fevertree,…

Read More
Lessons from the great investors

The chances are, most investors today will never have heard of Walter J Schloss. That’s a pity, as along with Warren Buffett and Charlie Munger he is one of the investing greats. From 1956 to 1984, Schloss’s firm compounded returns at a 21.3% annual rate after fees. In other words, he turned $1,000 into almost $328,000 for his investors. Over four and a half decades to 2000, when he closed his fund, Schloss achieved a compound annual return of 15.3%, turning $1,000 into roughly $623,000 after fees. Buffett himself described Schloss as a ‘super-investor’ due to his ability to spot…

Read More
Hutchmed (China) soars on GSK licence deal

Shares in drug developer Hutchmed (China) (LON:HCM) soared on news the firm had signed a licence deal with GSK (LON:GSK). The licence gives GSK worldwide rights, excluding China, Hong Kong and Taiwan, to develop and market one of Hutchmed’s cancer therapies. Licence deal with GSK Hutchmed has signed over the commercial rights to its KRAS-EGFR treatment HMPL-A830, with clinical trials expected to begin by year-end. Development will initially focus on colorectal, pancreatic and lung cancer indications. These cancers have the highest incidence of patients with KRAS-altered tumors, who often lack a safe and durable therapy. Hutchmed will be responsible for…

Read More
CRest Nicholson shares hit lifetime low on guidance cut

Shares in housebuilder Crest Nicholson (LON:CRST) hit a lifetime low after the latest cut to earnings guidance. The news also triggered selling in the shares of larger rivals Barratt Redrow (LON:BTRW) and Taylor Wimpey (LON:TW.). Another cut to earnings guidance In a trading update ahead of its financial year-end next month, Crest Nicholson lowered its completions target and EBIT guidance. The firm put the reduction down to weaker open-market demand, continued competitive pricing and continued build cost inflation. Completions are now expected to be between 1,350 and 1,400 against a previous target of 1,400 to 1,500 units. Meanwhile, EBIT is…

Read More